2012;23:745 754. 790. Lee M, Hong KS, Chang SC, Saver JL. Efficacy of homocysteine-lower- ing therapy with folic acid in stroke prevention: a meta-analysis. Stroke. 2010;41:1205 1212. 791. Righetti M, Serbelloni P, Milani S, Ferrario G. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif. 2006;24:379 386. 792. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of car- diovascular events in end-stage renal disease. J Am Soc Nephrol. 2004;15:420 426. 793. Zoungas S, McGrath BP, Branley P, Kerr PG, Muske C, Wolfe R, Atkins RC, Nicholls K, Fraenkel M, Hutchison BG, Walker R, McNeil JJ. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal fail- ure: a multicenter, randomized, controlled trial. J Am Coll Cardiol. 2006;47:1108 1116. 794. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565 575. 795. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lower- ing with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567 1577. 796. Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E; Heart Outcomes Prevention Evaluation 2 Investigators. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke. 2009;40:1365 1372. 797. Marcovina SM, Koschinsky ML. Evaluation of lipoprotein(a) as a pro- thrombotic factor: progress from bench to bedside. Curr Opin Lipidol. 2003;14:361 366. 798. 